source
- Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung diseaseRoivant Sciences reported that its inhaled candidate mosliciguat has successfully completed a Phase 2 trial in patients with interstitial lung disease. The study met its primary endpoint, showing a…
- Novartis shares tumble after late-stage failure of Avidity-acquired drugNovartis announced that its late-stage trial of a drug it acquired from Avidity did not meet its primary endpoints. The setback follows a recent disappointment in a heart disease study, adding pres…